Test Price
2,800 AED✅ Home Collection Available
RGS9 Gene Bradyopsia Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity for pathogenic variants via ISO‑validated NGS pipeline.
- VIP Mobile Phlebotomy: Temperature‑controlled home collection available daily 8 AM – 11 PM.
- Post‑Test Teleconsultation: Free genetic counselling call to interpret results.
- Insurance Verification: Direct WhatsApp check at +971 54 548 8731.
Test Overview & Methodology
The RGS9 Gene Bradyopsia Genetic Test screens for pathogenic variants in the RGS9 gene causing bradyopsia, a rare inherited retinal disorder characterised by markedly slow light‑to‑dark adaptation. This test utilises high‑coverage Next‑Generation Sequencing (NGS) on the Illumina platform to deliver a definitive molecular diagnosis, carrier status, and family risk assessment in compliance with DHA licensing standards.
| Feature | This Test (NGS) | Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity for point mutations, small indels, and exonic CNVs (confirmed by Sanger) | ~99% for known mutations, limited to coding regions |
| Method | NGS (Illumina) with integrated bioinformatics pipeline | Sanger sequencing of RGS9 coding exons |
| Turnaround Time | 3–4 weeks | 4–6 weeks |
Physician Insight & Safety Protocols
“This test provides critical molecular confirmation of bradyopsia, but clinical correlation with comprehensive ophthalmologic examination and electrophysiology remains essential. I encourage all patients to review the result within a dedicated genetic counselling session, ensuring that personal and family implications are fully understood before any clinical decision is made.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA ID: 9294403
Safety Advisory
Medication Advisory
Do not discontinue any prescribed medications without consulting your doctor. Pre‑test genetic counselling is mandatory for all patients.
Exclusion Criteria & Emergency Red Flags
Not suitable for:
- Acute eye emergencies (sudden vision loss, severe eye pain, ocular trauma)
- Patients unwilling to undergo pre‑test genetic counselling
- Minors without informed legal consent (as per UAE Federal Decree-Law No. 4 of 2016 on Medical Liability)
Seek immediate ER if you experience:
- Acute photophobia with headache and nausea
- Sudden shower of floaters, flashes of light, or a curtain‑like shadow across the visual field
- Significant eye pain or redness with vision decline
Patient FAQ & Clinical Guidance
1. What is the RGS9 Gene Bradyopsia NGS test, and how does it help?
This DNA test screens for mutations in the RGS9 gene associated with bradyopsia, a rare inherited retinal disorder causing slow light adaptation. It provides a definitive molecular diagnosis, informs prognosis, and enables genetic counselling for at‑risk family members.
2. When should I consider this genetic test?
Consider testing if you or a family member experience prolonged difficulty adapting from bright to dim light, especially when accompanied by normal visual acuity and colour vision. It is also indicated for carrier screening in families with known RGS9 mutations.
3. How is the sample collected and what should I expect?
A simple venous blood draw or a dried blood spot on an FTA card is all that is needed. Our DHA‑licensed VIP mobile phlebotomy team visits your home between 8 AM and 11 PM, ensuring cold‑chain transport to our ISO 9001:2015‑certified laboratory.
UAE Regulatory & Data Privacy Adherence
- Federal Decree-Law No. 45 of 2021 (PDPL): All genetic data handled with encryption and strict access controls.
- Federal Law No. 2 of 2019: Use of information and communication technology in health fields fully compliant.
- Federal Decree-Law No. 4 of 2016: Medical liability and patient consent verified for every procedure.
- ISO 9001:2015 Certified – Certificate: INT/EGQ/2509DA/3139.
Clinical & Logistical Metadata
| Test Name | RGS9 Gene Bradyopsia Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (Illumina NGS) + Sanger confirmation |
| ICD-10-CM Code | H53.72 |
| LOINC Code | 81247-9 |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians